Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 28;23(1):346.
doi: 10.1186/s12933-024-02434-5.

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review

Haixiang Zheng  1   2 , Leonardo Antonio Sechi  1   3 , Eliano Pio Navarese  4 , Gavino Casu  4 , Gianpaolo Vidili  5
Affiliations
Review

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review

Haixiang Zheng et al. Cardiovasc Diabetol. .

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease (NAFLD), poses a significant global health challenge due to its increasing prevalence and strong association with cardiovascular disease (CVD). This comprehensive review summarizes the current knowledge on the MASLD-CVD relationship, compares analysis of how different terminologies for fatty liver disease affect cardiovascular (CV) risk assessment using different diagnostic criteria, explores the pathophysiological mechanisms connecting MASLD to CVD, the influence of MASLD on traditional CV risk factors, the role of noninvasive imaging techniques and biomarkers in the assessment of CV risk in patients with MASLD, and the implications for clinical management and prevention strategies. By incorporating current research and clinical guidelines, this review provides a comprehensive overview of the complex interplay between MASLD and cardiovascular health.

Keywords: Cardiovascular risk; Metabolic dysfunction-associated steatotic liver disease; Metabolic-associated fatty liver disease; Nonalcoholic fatty liver disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Pathophysiological mechanisms linking MASLD to CVD (Created with BioRender.com). IR: insulin resistance, MASLD: metabolic dysfunction-associated steatotic liver disease, CVD: cardiovascular disease
Fig. 2
Fig. 2
Effect of MASLD on traditional cardiovascular risk factors (Created with BioRender.com). MASLD: metabolic dysfunction-associated steatotic liver disease
Fig. 3
Fig. 3
MASLD and its multifaceted CVD complications (Created with BioRender.com). MASLD: metabolic dysfunction-associated steatotic liver disease, CVD: cardiovascular disease
Fig. 4
Fig. 4
Potential preventive and therapeutic strategies for CVD risk in MASLD (Created with BioRender.com). MASLD: metabolic dysfunction-associated steatotic liver disease, CVD: cardiovascular disease, DM: diabetes mellitus, GLP-1: glucagon-like Peptide 1, SGLT-2: sodium glucose-linked transporter 2, ACEI: angiotensin-converting enzyme inhibitor, ARB: angiotensin receptor blocker, MASH: metabolic dysfunction-associated steatohepatitis, TZDs: thiazolidinediones
See this image and copyright information in PMC

References

    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. - PubMed
    1. Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691–702. - PubMed
    1. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–9. - PubMed
    1. Gofton C, Upendran Y, Zheng MH, George J. MAFLD: how is it different from NAFLD? Clin Mol Hepatol. 2023;29(Suppl):S17–31. - PMC - PubMed
    1. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542–56. - PubMed

Publication types

MeSH terms

LinkOut - more resources